AJMC Staff

A second biosimilar to infliximab, marketed as Remicade by Johnson & Johnson, has received FDA approval. Infliximab-abda (Renflexis) was developed by Samsung Bioepis/Merck and has been approved for multiple indications.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

A new collaboration between the Duke Clinical Research Institute, Duke University’s MURDOCK Study, and Boehringer Ingelheim Pharmaceuticals Inc will try to better understand how chronic obstructive pulmonary disease progresses in the real world.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

Researchers developed a new framework that can predict long-term outcomes of different therapeutic options for Gaucher disease type 1.

Hispanics and blacks with colorectal cancer report a higher burden of poor health-related quality of life (HR-QoL) compared with white patients, according to study results presented at the annual meeting of the American Association for Cancer Research.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

Patients with chorea associated with Huntington’s disease have the first new treatment in nearly a decade. The FDA has approved Teva Pharmaceutical Industries Ltd’s Austedo (deutetrabenazine) for the treatment of chorea, which affects nearly 90% of patients with Huntington's.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

Coverage of our peer-reviewed research in the healthcare and mainstream press.